This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Exosome Presents Late-Breaking Study Demonstrating Ability To Profile RNA From Archived Clinical Trial Blood Samples At 2013 American Association Of Cancer Research Annual Meeting

NEW YORK, April 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.  The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by Johan Skog, Ph.D., the newly appointed chief scientific officer of Exosome Diagnostics.   

In this study, Exosome Diagnostics used its proprietary RNA-extraction technology to measure a broad spectrum of full-length mRNA and microRNA from low volumes (2 mL) of frozen, archival serum from brain cancer patients enrolled in a therapeutic clinical trial.  Prior to the introduction of Exosome Diagnostics' technology, similar biomarker analysis would have required performing invasive brain tissue biopsies.

This clinical study represents the third biofluid in which Exosome Diagnostics has demonstrated the ability to harvest disease-specific RNA biomarkers.  Data have been presented in clinical studies from different disease groups from urine, blood, and cerebrospinal fluid exosome preparations.

"Extraction of high-quality RNA, particularly intact messenger RNA, from blood, urine or CSF samples is an important advance for discovering and measuring both known and novel biomarkers for patient selection and drug response," said Johan Skog, Ph.D.  "This study demonstrates that frozen and archived biofluid samples can be interrogated for gene expression along with fresh samples in patient populations of interest to clinical investigators and drug developers."

James McCullough, chief executive officer of Exosome said, "Rapid, reproducible extraction of high quality RNA with appropriate internal quality control from frozen blood samples satisfies an important request from our pharmaceutical partners to unlock the potential of their vast clinical trial bio-banks.  We are now firming plans to launch an Exosome Diagnostics life sciences kit product line in early 2014 to enable drug developers and researchers to pursue biomarker discovery in cancer, CNS and other diseases."   

Exosomes are microscopic packages shed by all cells into biofluids such as blood, urine and cerebrospinal fluid.  Exosomes protect an abundance of active genetic material (ribonucleic acid or "RNA") that, when properly harvested, can produce accurate molecular diagnostic measurements using standard PCR and sequencing instruments.  In addition to its planned life science product line, Exosome Diagnostics has been conducing multi-center clinical validation studies in partnership with the Prostate Cancer Foundation for the first-ever regulated exosome in vitro diagnostic, which targets early stage prostate cancer from a random patient urine sample. 

About Exosome DiagnosticsExosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is developing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. For more information, please visit www.exosomedx.com.

SOURCE Exosome Diagnostics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs